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A B S T R A C T
Supersaturated lipid-based drug delivery systems have recently been investigated for oral administration for a
variety of lipophilic drugs and have shown either equivalent or superior oral bioavailability compared to con-
ventional non-supersaturated lipid-based drug delivery systems. The aim of the present work was to explore
supersaturated versus non-supersaturated lipid-based systems at equivalent lipid doses, on in vivo bioavailability
in rats and on in vitro permeation across a biomimetic PermeapadⓇ membrane to establish a potential in vivo - in
vitro correlation. A secondary objective was to investigate the influence of lipid composition on in vitro and in
vivo performance of lipid systems. Results obtained indicated that increasing the celecoxib load in the lipid-based
formulations by thermally-induced supersaturation resulted in increased bioavailability for medium and long
chain mono-/di-glycerides systems relative to their non-supersaturated (i.e. 85%) reference formulations, albeit
only significant for the medium chain systems. Long chain systems displayed higher celecoxib bioavailability
than equivalent medium chain systems, both at supersaturated and non-supersaturated drug loads. In vitro
passive permeation of celecoxib was studied using both steady-state and dynamic conditions and correlated well
with in vivo pharmacokinetic results with respect to compositional effects. In contrast, permeation studies in-
dicated that flux and percentage permeated of supersaturated systems, either at steady-state or under dynamic
conditions, decreased or were unchanged relative to non-supersaturated systems. This study has shown that by
using two cell-free PermeapadⓇ permeation models coupled with rat-adapted gastro-intestinal conditions, bio-
predictive in vitro tools can be developed to be reflective of in vivo scenarios. With further optimization, such
models could be successfully used in pharmaceutical industry settings to rapidly screen various prototype for-





aDS Apparent degree of saturation
ANOVA Analysis of variance
AUC Area under the plasma concentration-time curve
CCX Celecoxib
Cmax Maximum plasma concentration
GI Gastro-intestinal
IBU Ibuprofen
IVIVC In vitro-in vivo correlations
LBDDS Lipid-based drug delivery systems
LC Long chain
LCM Long chain mono-/di-glycerides
MC Medium chain
MCM Medium chain mixed glycerides
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PWSDs Poorly water-soluble drugs
RP-UPLC Reversed-phase Ultra Performance Liquid Chromatography
(UPLC™)
rSIF Rat simulated intestinal fluid
S Surfactant
Seq Equilibrium solubility
sLBDDS Supersaturated lipid-based drug delivery systems
tmax Time to reach maximum plasma concentration
1. Introduction
With numerous commercial successes, lipid-based drug delivery
systems (LBDDS) have a proven track record to improve oral absorption
of poorly water-soluble drugs (PWSDs) through a variety of mechan-
isms including increasing solubility, reducing food-induced exposure
variability and improving overall intestinal uptake (Savla et al., 2017).
To-date the merits of LBDDS have been limited to a relatively small
number of highly lipophilic drugs, and a key drawback is that the dose
of drug that can be loaded in LBDDS is hindered by the drug solubility
in lipids (Thomas et al., 2012; Michaelsen et al., 2016). The need to
administer high doses of PWSDs by the oral route, such as in pre-clinical
safety and toxicological evaluation, has expanded the potential for use
of supersaturated lipid-based drug delivery systems (sLBDDS)
(Siqueira Jørgensen et al., 2018). While risks of insufficient stability on
long term storage remain a challenge to successful exploitation of
sLBBDS as clinical formulations, a recent study has demonstrated that
stability of selected sLBDDS is suitable for a preclinical setting to
maximise drug exposure (Ilie et al., 2020a). Pharmacokinetic studies
involving sLBDDS have indicated an improved in vivo performance re-
lative to conventional non-supersaturated LBDDS or aqueous suspen-
sion for a range of either weakly basic or neutral drugs including ha-
lofantrine (Thomas et al., 2012; Michaelsen et al., 2016), simvastatin
(Thomas et al., 2013), fenofibrate (Thomas et al., 2014) and R3040
(Siqueira Jørgensen et al., 2018) in different preclinical species (i.e. rat,
dog and mini-pig). The most commonly described preparation method
for sLBDDS is heating the drug together with the lipid excipients to
50–60°C, followed by cooling to ambient temperature. To-date the vast
majority of these studies have used a well characterized lipid-surfac-
tant-co-solvent mixture (i.e. Soybean oil + Maisine CC or Captex
300 + Capmul MCM (55%) as lipid components, Kolliphor RH40 (35%)
and ethanol (10%), w/w%) as the delivery vehicle. However, given the
compositional complexity of this specific LBDDS, involving three lipidic
excipients plus a co-solvent, it would be preferable to consider less
complex LBDDS that can be rapidly screened in an industrial drug de-
velopment setting (Holm, 2019; Savla et al., 2017; Müllertz et al.,
2010).
Various in vitro tools are commonly used for biopharmaceutical
characterisation of prototype formulations, with an increasing focus on
developing in vitro tests that are predictive of or at least provide me-
chanistic insights into the critical steps involved in oral absorption in
vivo. For LBDDS, a range of in vitro dilution, dispersion and dynamic
(gastro-)intestinal (GI) lipolysis tests with pH-titration have been em-
ployed (Griffin et al., 2014; Kleberg et al., 2014; Berthelsen et al.,
2019). Optimization of biorelevant media to match the rats GI condi-
tions (i.e. lower enzymatic activity and dilution volumes, higher bile
salt and lipid concentrations) have proven useful to predict the in vivo
performance in a two-stage GI in vitro model of furosemide
(Christfort et al., 2019), in silico models (Berghausen et al., 2016), and
in two digestion models using danazol or R3040 LBDDS (Anby et al.,
2014; Siqueira Jørgensen et al., 2018).
Despite the advances in optimising digestion conditions to more
closely match the in vivo scenario, overall a limited number (50%) of in
vitro-in vivo correlations (IVIVC) have been observed for LBDDS based
on comparing drug solubilisation in the aqueous phase of the digestion
medium from the standard in vitro lipolysis model and the in vivo drug
absorption (Feeney et al., 2016). As a result, the focus has shifted to-
ward exploration of models that simultaneously assess the interplay
between digestion and drug permeation by incorporating a permeation
compartment in the classical digestion models (Buckley et al., 2013). In
addition, there is a need to advance models that mechanistically can
explore the interplay between free drug (i.e. molecularly dissolved) and
drug bound as its colloidal associates, given it has been suggested that
free drug can permeate across biological or artificial membranes,
whereas drug solubilised within colloidal species may not
(Williams et al., 2013b; Berben et al., 2018). Several studies have
shown that the concentration of molecularly dissolved drug provides
the driving force for absorption while using different solubilising
agents: non-ionic surfactants (Fischer et al., 2011a; Fischer et al.,
2011b), cyclodextrins (Dahan et al., 2010) or bile-salt micelles in si-
mulated intestinal fluid (Frank et al., 2012). Berthelsen et al. have re-
cently compared six combined digestion-permeation models, under-
lining the potential for an improved IVIVC using either the cell-free
biomimetic membrane PermeapadⓇ or the Caco-2 cell monolayers as
permeation barriers (Berthelsen et al., 2019). Specifically, Keemink and
co-workers developed a two-compartment model to simultaneously
study the digestion-permeation interplay using Caco-2 cell monolayers
in a cone-shaped digestion vessel (Keemink et al., 2019). Thus, the two-
stage model correctly predicted the rank order of the in vivo perfor-
mance in pigs of three fenofibrate LBDDS and the carvedilol absorption
in dogs after administration as dissolved in LBDDS or co-administered
with LBDDS (Keemink et al., 2019; Griffin et al., 2014; Alskär et al.,
2019). While the use of the integrated Caco-2 based model has de-
monstrated impressive results, it should also be acknowledged that the
complexity of this experimental setup limits its more widespread ap-
plication as a screening tool in the pharmaceutical industry. Another
mechanism to mimic absorption of drug in the intestine is via the use of
an organic layer, such as octanol or decanol, as part of the in vitro setup.
Recently, O'Dwyer and co-workers proposed a two-stage biphasic li-
polysis setup, incorporating a gastric-to-intestinal transition with a
layer of decanol acting as an absorptive compartment. This setup was
tested using LBDDS containing three model drugs (nilotinib, fenofibrate
and danazol) and was found to more reliably predict in vivo bioavail-
ability compared to the standard pH-stat method (O'Dwyer et al.,
2020).
Alternatively, the biomimetic artificial barrier, PermeapadⓇ, offers a
cell-free approach to screen formulations in a simultaneous digestion-
permeation model (Bibi et al., 2017). PermeapadⓇ consists of a phos-
phatidylcholine layer immobilized between two cellulose-based support
sheets, which has been used to evaluate drug (passive) permeability and
to screen drug formulations (Di Cagno et al., 2015; Bibi et al., 2017;
Jacobsen et al., 2020). Bibi et al. demonstrated that the membrane was
compatible with the conventional LBDDS digestive conditions in a side-
by-side permeation setup in static conditions. While this side-by-side
cell-free model was useful for exploring differences in steady-state flux
of free versus solubilised drug, the PermeaLoop™ model was developed
to better mimic the continuous and dynamic flow conditions in the
intestine (Sironi et al., 2018). The Permealoop™ model addressed a
shortcoming of the restricted permeation area with the current side-by-
side static setup and provided the possibility of using a more physio-
logically relevant area-to-volume ratio (i.e. 1.38 cm−1 A/V), whereby
physiological A/V values were estimated to be between 1.9 cm−1 and
2.3 cm−1 for dissolution evaluation of amorphous solid dispersion of
ABT-869 (Berben et al., 2018; Sironi et al., 2018).
The overall aim of the present study was to explore the impact of
supersaturation in LBDDS on the permeation and absorption of the
model drug celecoxib, relative to 85% saturated LBDDS. To the best of
our knowledge, this was the first study to explore impact of sLBDDS
versus conventional non-supersaturated LBDDS in combined disper-
sion/digestion-permeation setups, and under steady-state and dynamic
flow conditions. The specific objectives could be summarised as: 1) to
compare in vivo bioavailability of celecoxib in rats across a range of
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supersaturated and non-supersaturated LBDDS; 2) to evaluate the in-
fluence of supersaturation, compositional effects and digestive state on
permeation across PermeapadⓇ using the side-by-side diffusion cells
setup, and 3) to assess supersaturation and compositional effects on
drug permeation in a dynamic permeation setup using PermeaLoop™.
Finally, in order to improve predictability of the in vitro models, in vitro
conditions were adapted to mimic in vivo conditions for pH, bile salts
composition, pancreatic enzyme activity and dose:volume considera-
tions for rats.
2. Materials and methods
2.1. Materials
The poorly water-soluble drug used in this study was celecoxib
(CCX, weak acid, 381.4 g/mol, logP=4.3), and was purchased from
Astatech Inc. (Bristol, PA, USA). Ibuprofen was used as internal stan-
dard for plasma analysis and was obtained from Janssen Pharmaceutica
(Beerse, Belgium). CapmulⓇ MCM C8 (medium chain mixed glycerides,
MCM) was kindly donated by Abitec (Columbus, OH, USA). MaisineⓇ
CC (long chain mono-/di-glycerides, LCM) and LabrasolⓇ ALF (capry-
locaproyl polyoxyl-8 glycerides, subsequently denominated as surfac-
tant, S) were kind gifts from Gattefossé (Lyon, France).
Porcine pancreatic lipase 4x USP, calcium chloride dihydrate
CaCl2⋅2H20, 4-bromophenyl-boronic acid (4-BBBA) and maleic acid
were purchased from Sigma-Aldrich Denmark ApS (Brøndby,
Denmark). Sodium hydroxide was purchased from Merck A/S
(Hellerup, Denmark) and polysorbate 80 was acquired from Fluka
(Buchs, Switzerland). Purified water was freshly prepared using a Milli-
QⓇ integral water purification system (Milli-Q Advantage A10;
MerckMillipore, Merck A/S, Hellerup, Denmark). Rat simulated in-
testinal fluid (rSIF) powder was prepared according to a publication by
Berghausen and co-workers (Berghausen et al., 2016) and had the fol-
lowing components: sodium taurocholate 5 mM, sodium cholate hy-
drate 12.5 mM, sodium chenodeoxycholic acid 7.5 mM, lecithin
5.16 mM, sodium oleate 0.26 mM and glyceryl monooleate 1.67 mM.
PermeapadⓇ phospholipid-based membranes were provided by innoMe
(Espelkamp, Germany). All other chemicals and solvents were of ana-
lytical or HPLC grade if not stated otherwise and were purchased from
VWR (Denmark or Belgium).
2.2. Methods
2.2.1. Design of celecoxib-loaded lipid-based drug delivery systems
Based on initial equilibrium solubility (Seq) measurements of three
replicates at 37°C the amounts corresponding to 85% mean Seq
(Table 1) were weighed into clean screw-top glass vials and drug-free
lipid systems were added up to achieve the target drug concentration.
Vials were sealed, mixed and incubated at 37°C for 24 h prior to testing.
Similarly, based on Seq measurements at 60°C, supersaturated LBDDS
were prepared by adding 85% of Seq C60
0
to the lipid systems and heating
the mixture at 60°C for 24 h, followed by cooling to ambient tem-




values of celecoxib in the LCM, MCM and
LCM+S systems have been reported previously (Ilie et al., 2020a);
however, in the case of MCM+S systems some modifications had to be
made. Firstly, the 80.9 mg/mL value for 85% saturated MCM+S is
based on an initial solubility triplicate dataset (Seq C37
0
= 95 ± 57 mg/
mL) which preceded the publication of solubility data (Ilie et al.,
2020a). After the in vivo study was performed, it was decided that due
to high variability, these measurements should be repeated and thus the
reported values are as 138 ± 16 mg/mL in the published study
(Ilie et al., 2020a). In addition, we found that the freshly prepared
sMCM+S formulation, prepared with 219.3 mg/mL (i.e. 85% of
258 ± 51 mg/mL) did not produce a clear system, with evidence of
drug precipitation after cooling to ambient temperature. Therefore, the
actual concentration of the drug in the system (after centrifugation) was
determined and reported in Table 1 (128.4 mg/mL). Given the issues
observed in this freshly prepared MCM+S system, the Seq C37
0
was de-
termined again in this specific batch (i.e. 112. 7 ± 6.0 mg/mL).
Overall, with these modifications, all final formulations produced clear
solutions, with no macroscopic evidence of drug precipitation upon
cooling. In addition, drug concentration in the designed (s)LBDDS was
confirmed analytically prior to in vitro testing. The saturation degree
was calculated relative to Seq C37
0
and is listed in Table 1 as apparent
degree of saturation (aDS) as previously described (Ilie et al., 2020a).
Using the above-mentioned values for the MCM+S system, the 114%
aDS for sMCM+S was calculated. Evaluation of the one- and two-
component 85% saturated and supersaturated LBDDS was performed in
two separate pharmacokinetic rat studies and only the one-component
systems were investigated in permeation studies.
2.2.2. Pharmacokinetic evaluation of lipid-based drug delivery systems
The protocol used for the in vivo pharmacokinetic evaluation of (s)
LBDDS was approved by the institutional animal ethics committee in
accordance with the Belgian law regulating animal use in experimental
procedures. The study was in compliance with EC Directive 2010/63/
EU and the NIH guidelines on animal welfare. Fasted male Sprague-
Dawley rats weighing between 250 and 300 g received 0.5 mL/kg
celecoxib-loaded 85% saturated or supersaturated LBDDS (n = 4) by
oral gavage. Lipid systems were stirred continuously the night before
dosing and were clear upon oral administration. 200 µL of whole blood
was collected at defined time points: 0.5, 1, 2, 4, 6, 8, 24 h, 100 µL
plasma was harvested by centrifugation and bioanalysis was performed
on a Waters UPLC™ system with UV-detection. The corresponding dose
and aDS for each LBDDS are shown in Table 1. To obtain the absolute
bioavailability, celecoxib was also dosed intravenously (i.v.) as an in-
tralipid emulsion (plasma profile not shown). The vehicle of the in-
tralipid emulsion consisted of sesame oil (20.0%, w/w), lecithin (1.2%,
w/w), glycerol (2.0%, w/w) and water (76.8%, w/w). Celecoxib, se-
same oil and lecithin were mixed and slowly stirred until all celecoxib
was dissolved while heating at 60°C. Water and glycerol were mixed
and heated at 60°C. When oil phase was ready, the two phases were
mixed and homogenised with the IKA T18 digital Ultra Turrax (IKA
Works, Inc., NC, USA) at 24 000 rpm for 5 min and the pre-emulsion
was then passed through the GEA Panda Plus 200 high pressure
homogeniser 2000 (Düsseldorf, Germany) at 1200 bars for 10 cycles.
2.2.2.1. Quantitative analysis of plasma samples. Quantification of
celecoxib in plasma after oral dosing of the eight LBDDS was
performed using similar reversed-phase UPLC™ (RP-UPLC™) methods
Table 1
Amount corresponding to 85% mean Seq, doses (mg/kg) and apparent degree of saturation (aDS) of orally administered (s)LBDDS.
LBDDS Composition (w:w) 85% saturated LBDDS Supersaturated LBDDS
Drug concentration (mg/mL) Dose (mg/kg) aDS Drug concentration (mg/mL) Dose (mg/kg) aDS
LCM Long chain mono-/di-glycerides 15.8 7.9 85% 30.8 15.4 166%
MCM Medium chain mixed glycerides 57.4 28.7 85% 74.8 37.4 110%
LCM+S Long chain mono-/di-glycerides: surfactant (4:1) 62.2 31.1 85% 98.6 49.3 135%
MCM+S Medium chain mixed glycerides: surfactant (4:1) 80.9 40.5 85% 128.4 64.2 114%
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with ibuprofen (IBU) as internal standard as indicated by Knopp et al.
(Knopp et al., 2016). Ibuprofen was dissolved in acetonitrile to obtain
the internal standard solution and 140 µL of this solution was added to
20 µL plasma sample containing celecoxib. Separation of precipitated
plasma proteins was successful after centrifugation for 30 min at
17,500 rpm at 4°C using an Eppendorf centrifuge 5430R (Eppendorf,
Hamburg, Germany). The concentrations of celecoxib were determined
by standard calibration curve analysis using linear fitting of a plot of
CCX/IBU peak area ratios versus celecoxib concentrations. The
standard calibration curve was linear in the range 10 – 5000 ng/mL
and the lowest limit of quantification was 10 ng/mL. A RP Waters
Acquity BEH C18, 50 mm × 2.1 mm column packed with 1.7 μm
particles (Waters, Milford, USA) was used for the chromatographic
analysis with a mobile phase containing a mixture of solvents 0.1%
trifluoracetic acid in water: 100% acetonitrile – ACN under a gradient
program (0.3 min - 60:40, 2.3 min - 0:100, 2.7 min - 60:40 v:v). The
flow rate of the mobile phase was 0.60 mL/min and the injection
volume was 2 μL. The column temperature was maintained at 55°C and
the wavelength was monitored at 251 nm.
2.2.2.2. Pharmacokinetic and statistical analysis. The primary
pharmacokinetic parameters: area under the plasma concentration-
time curve (AUC), maximum plasma concentration (Cmax) and time to
reach Cmax (tmax) were obtained by non-compartmental analysis of the
plasma data, using the linear trapezoidal method in Microsoft Excel
(Office 365) with PKSolver add-in. Multiple sample comparison was
performed on dose-normalized pharmacokinetic parameters Cmax, tmax
and AUC0–24 h by a two-way analysis of variance (ANOVA) with
interaction of two factors (i.e. aDS and LBDDS composition) using
SigmaPlot 12.5 from Systat Software, Inc. (Chicago, IL, USA). A p-value
< 0.05 was considered significant and for statistical contrast analysis, a
Tukey post-hoc test was used. Results are expressed as mean ± SD for
Cmax and AUC0–24 h and median [min, max] for tmax.
2.2.3. Permeation studies with lipid-based drug delivery systems
Based on the higher in vivo drug exposure as a result of the ther-
mally-induced drug supersaturation and the positive influence of one-
component LC LBDDS on in vivo performance it was decided to com-
paratively evaluate the in vitro permeation of celecoxib between the
supersaturated and non-supersaturated LBDDS composed of only one
component (i.e. LCM or MCM). The permeation behaviour of celecoxib
LBDDS was firstly evaluated by an in vitro passive diffusion experiment
across a biomimetic membrane in a setup with side-by-side diffusion
cells (PermeaGear Inc., Hellertown PA, USA) at 37°C. The side-by-side
setup had a donor volume of 7 mL, an acceptor volume of 5 mL and the
effective diffusion area was 1.77 cm2. The donor phase was represented
by either dispersions or digests of the 85% saturated or the super-
saturated LCM or MCM formulations containing celecoxib. The pre-
paration of the donor media, dispersed and digested, is described below
in Section 2.2.3.2 and 2.2.3.3, respectively. The acceptor medium was
represented by an 1% (w/v) Polysorbate 80 (PS80) solution prepared in
PBS buffer pH 6.5 to ensure sink conditions. To assemble the permea-
tion setup, the PermeapadⓇ membranes were mounted between the
donor and acceptor compartments according to the manufacturer's
specifications. Samples from the acceptor compartment were drawn
every 30 min over a period of up to 5 h. After every sampling, the
acceptor was refilled with 1% PS80 solution to maintain volume and
sink conditions. The samples were analysed by UHPLC-UV as described
below. The cumulative amount of celecoxib that permeated across the
PermeapadⓇ membrane was normalized by the permeation area and
plotted against time. From the linear part of this graph the celecoxib
steady-state flux was derived (R2 > 0.99 between 1.5 and 5.0 h) (one
example in Supplementary information, Figure S1). Additionally, be-
cause the concentrations of drug between the different LBDDS, the
percentage permeated was calculated as means to normalize between
the different doses in the LBDDS according to Eq. (1), where amount in
donor is measured at the start of the experiment
= =
=
Cumulative amount determined in the acceptor compartment t h
Amount in donor dispersed digested t h
% permeated ( 5 )
( , ) ( 0 )
(1)
Steady-state flux values and % permeated were statistically ana-
lysed using a one-way ANOVA followed by Tukey's post-hoc test.
Additionally, dispersions of non-supersaturated and supersaturated
LCM and MCM were investigated using the PermeaLoop™ model. The
setup consists of three parts: donor and acceptor reservoirs (beakers
with internal diameter of 3 cm), peristaltic pump, and custom-made
permeation cells (Fig. 1). A volume of 20 mL of homogeneous disper-
sions of (s)LBDDS in rSIF (pH = 6.0) was added in the donor beakers.
As acceptor medium, a volume of 35 mL 1% PS80 solution was used to
ensure excess solubilization capacity of celecoxib and, thus, sink con-
ditions. Both compartments were stirred continuously at 500 rpm with
a rod-shaped stir bar (13 mm × 3 mm) on a multi-position magnetic
stirrer (MIXdrive 6 MTP, 2mag AG, Munich,Germany). The media were
continuously pumped through the permeation cells at a flow rate of
0.8 mL/min with a peristaltic pump (MCP Standard, Cole-Parmer
GmbH, Wertheim, Germany) through TYGON S3™ E-LFL tubes (Is-
matec, Wertheim, Germany). Pre-saturation of tubes was done using a
50 µg/mL celecoxib solution in rSIF which was recirculated for 1 h prior
to start of experiment.
The custom-made permeation cells consist of three aluminium
blocks in which a narrow, spiral-shaped channel has been milled out
(Fig. 1). Between each cell, a PermeapadⓇ membrane was mounted,
leading to a donor compartment (middle cell) and two acceptor com-
partments (top and bottom cell). The total permeation area was 27.64
cm2, and hence, the A/V was 1.38 cm−1. The cells were perfused with a
co-current flow and the media were re-circulated into the respective
beaker. The permeation study was performed at 37°C in a climate
chamber in triplicate. Samples (150 µL) were taken every 30 min for 4 h
from the acceptor beaker and replaced with fresh acceptor medium.
The cumulative amount of celecoxib that permeated across the
PermeapadⓇ membrane over the 4 h of study in the PermeaLoop™ setup
Fig. 1. Schematic representation of PermeaLoop™ model (adapted from Sironi et al.).
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was calculated and plotted against time (Fig. 4). As suggested before,
the percentage permeated was also calculated as means to normalized
between the different (s)LBDDS according to Eq. (2) where the amount




Cumulative amount in acceptor compartment t h
Amount in donor dispersed t h
% permeated ( 4 )
( ) ( 0 )
(2)
Cumulative amount and % permeated values were statistically
analysed using a one-way ANOVA followed by Tukey post-hoc test.
2.2.3.1. Preparation of rat simulated intestinal fluid. Rat simulated
intestinal fluid (rSIF) was prepared according to Berghausen et al.
who investigating nine compounds with different physico-chemical
properties and concluded that the incorporation of rSIF equilibrium
solubility values into in silico models of oral drug exposure can
significantly improve the accuracy of simulations in rats for doses up
to 300 mg/kg compared to other media (Berghausen et al., 2016). In
short, the solid components (sodium taurocholate, sodium cholate
hydrate, sodium chenodeoxycholic acid, lecithin, sodium oleate and
glyceryl monooleate) were dissolved in a blend of tert‑butanol and
water (9:1, w/w) under stirring and gentle warming to 40°C for 1 h
(Berghausen et al., 2016). The solution was divided into aliquots, frozen
in a freezer (−21 °C), transferred to a pre-cooled freeze-dryer (Christ
Gamma 2–16 LSC; Martin Christ GmbH, Osterode am Harz, Germany)
with a plate temperature of ≤ −45 °C and freeze dried. During primary
drying (overnight), the plate-temperature was steadily to +25 °C while
the chamber-pressure was maintained constant at 0.1 mbar. During
secondary drying (4 to 8 h), the plate with the vials was maintained at a
temperature of 25 °C and the chamber pressure lowered to ≤0.01 mbar.
The freeze-dried powder was stored in a desiccator until use.
Rehydration was performed with sodium maleate buffer (0.216 g
sodium chloride and 0.695 g maleic acid in 200 mL Milli-Q water, pH
2.0), stirred for 24 h at room temperature and finally pH was adjusted
to 6.0 with NaOH 0.5 M.
2.2.3.2. Dispersions of lipid-based drug delivery systems. LBDDS at either
the 85% or at the supersaturated drug loadings were dispersed in rat SIF
(pH 6.0) in a 1:30 ratio to be consistent with the volume administered
to the rats (~150 µL/rat) and considering that the volume of intestinal
fluid measured in rats in the fasted state would be 4.5 mL based on the
reported range by McConnell and co-workers, 3.2 ± 1.8 mL
(McConnell et al., 2008). Dispersions were stirred for 10 min at
300 rpm, 37°C to ensure homogeneity prior to transfer to donor
diffusion cell or to the PermeLoop™ donor beaker. The total drug
concentration (dissolved and dispersed) in this dispersion medium was
measured with the UHPLC-UV method described below and used for
calculation of percentage permeated.
2.2.3.3. Digestion of lipid-based drug delivery systems. A digestion
medium that mimics the rat intestinal conditions was formulated by
dissolving CaCl2⋅2H20 in rat SIF (5 mM) before starting the digestion,
instead of continuous addition of Ca2+ while digestion progresses,
according to a protocol published by Bibi and co-workers (Bibi et al.,
2017). Subsequently, the pH was adjusted to 6.5 with NaOH 0.5 M to be
consistent with previously tested digestion setups (Bibi et al., 2017).
LBDDS were dispersed in the same 1:30 ratio (v:v) as for dispersions
described above, in a heated vessel inside of an oven at 37°C.
Digestion was initiated by addition of pancreatin supernatant pre-
pared by suspending the pancreatic extract in rat digestion buffer,
which was prepared 10 min prior to use, to limit denaturation. The
supernatant was prepared by gentle vortex of the pancreatic extract into
rat digestion buffer containing Ca2+. Enough pancreatic extract was
added to obtain a rat relevant lipase activity of 179 USP units (USPU/
mL) as indicated by Siqueira Jørgensen et al. (Siqueira Jørgensen et al.,
2018). When homogenous, the mixture was centrifuged (5804 R cen-
trifuge equipped with a F-34–6–38 rotor, Eppendorf, Hamburg, Ger-
many) at 4000 rpm for 7 min, at 37°C. The supernatant was collected
and transferred to the digestion beaker in a 1:9 ratio (v:v), as previously
described (Kleberg et al., 2014). In a preliminary digestion study, the
pH was monitored to determine the extent of digestion after 1, 2, 3, and
24 h according to a design by Mosgaard et al. and pH values are shown
in Table S 1, Supplementary information (Mosgaard et al., 2015). It was
concluded that after 1 h digestion most of LCM and MCM LBDDS was
digested as a large pH drop was registered in the first hour, followed by
a relatively small decrease at latter timepoints. Celecoxib was also
quantified in the digests and the concentration was used for calculation
of percentage permeated. After each collection of (s)LCM or (s)MCM
digests, 4-BBBA was added to inhibit further lipolysis.
2.2.3.4. Celecoxib quantification in donor and acceptor
compartments. Quantification of celecoxib was conducted on a
Thermo Fisher UltiMate 3000 UHPLC system that was connected to a
Diode Array detector and equipped with an RP KinetexⓇ EVO C18 LC-
column (100 × 2.1 mm; particle size 1.7 µm; pore size 100 Å,
PhenomenexⓇ). The injection volume was 5 µL, flow rate was set at
0.3 mL/min and the mobile phase consisted of 55% (v/v) purified water
containing 0.1% (v/v) trifluoroacetic acid as modifier and 45% (v/v)
acetonitrile (isocratic elution). The column oven temperature was set to
40°C. The total run time was 4 min and celecoxib eluted after 2.1 min
with a detection wavelength of 251 nm. The method was linear in the
range 10 - 5000 ng/mL for side-by-side results and 100 - 10 000 ng/mL
for PermeaLoop™ data.
3. Results
3.1. Comparing in vivo bioavailability of supersaturated versus non-
supersaturated lipid-based drug delivery systems
A range of supersaturated LBDDS were prepared by adding a fixed
amount of drug (based on 85% of Seq C60
0
, heating to 60°C for 24 h and
leaving to cool at ambient temperature prior to oral administration to
rats. As outlined in Table 1, aDS ranged between 110 and 166%, de-
pending on the composition. For each formulation, the corresponding
non-supersaturated LBDDS was prepared at 85% of the saturation so-
lubility. In general, the aDS of MC systems (i.e. MCM and MCM+S)
were lower than the aDS for LC systems (i.e. LCM and LCM+S). This
reflected the higher solubility of the drug in MC systems relative to LC
systems and overall lower propensity for thermally-induced super-
saturation (Ilie et al., 2020a). In all cases, the dosing volume of 0.5 mL/
kg was maintained across all tested lipid systems to ensure the total
volume of lipid administered was constant between treatment groups.
As a result, the celecoxib dose was different between groups depending
on the drug solubility in each system (Table 1). To facilitate direct
comparison between the LBDDS in terms of saturation degree and
compositional effects, the celecoxib plasma concentrations were dose-
normalized (Fig. 2). The corresponding pharmacokinetic parameters
are presented in Table 2 and a comparison of dose-normalized
AUC0–24 h plotted against LBDDS composition is illustrated in Fig. 3.
Absolute bioavailability (F%) was determined with respect to an i.v.
administration (1 mg/kg) of a submicron emulsion with celecoxib
(1 mg/g) (n = 4) (mean = ±AUC 4030 271 ng/mL*hhri v0 24. . ).
With respect to the absorption (AUC0–24 h), thermally-induced su-
persaturation resulted in a trend towards increasing AUCs for single
component systems relative to non-supersaturated systems, which was
statistically significant for MCM, but not for LCM. This increase in
AUC0–24 h translated to an increase of 14.5% in the absolute bioavail-
ability for sLCM versus LCM (p = 0.200) and 40.9% for sMCM versus
MCM (p = 0.001). An increase in rate of absorption (Cmax) was also
observed for sLCM and sMCM versus their non-supersaturated corre-
spondents, albeit not statistically significant. In terms of tmax,
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statistically significant prolongation was observed for sLCM versus
LCM. In surfactant-containing systems no trends were apparent with the
extent and rate of absorption being similar between supersaturated and
non-supersaturated systems after dose-normalization, with mean abso-
lute bioavailability values of 76.6% and 77.6% for (s)LCM+S and
54.7% and 68.9%% for (s)MCM+S, respectively.
With regards to compositional effects, the overall observed trend for
the extent absorbed increased after administration of LC systems re-
lative to MC systems, which was statistically significant for non-su-
persaturated systems (LCM and MCM), but not for sLBDDS (sLCM and
sMCM). The better in vivo performance of the LCM system, either non-
supersaturated or supersaturated, is also shown by the rate of absorp-
tion which showed statistically significantly higher Cmax values relative
to the corresponding MC systems (MCM and MCM+S). Furthermore, a
statistically significant increase was identified for Cmax and AUC0–24 h of
sLCM and for AUC0–24 h of sMCM relative to surfactant-containing
sMCM+S. Finally, the statistical evaluation confirmed an interaction
between the two factors aDS and composition for AUC0–24 h and ab-
solute bioavailability. Therefore, this may indicate that the in vivo ef-
fects are the result of interplay between the factors and not just in-
dividual factors.
3.2. Influence of supersaturation, compositional effects and digestive state
on in vitro steady-state permeation across PermeapadⓇ
The mean celecoxib steady-state flux of (s)LCM and (s)MCM systems
Fig. 2. Plasma concentration-time profiles (mean + SD),
n = 4 for celecoxib after dosing four LBDDS at 85% drug
concentration (continuous lines) and supersaturated drug
concentration (interrupted lines). The tested LBDDS were
LCM (full circles), MCM (empty circles), LCM+S (full
squares) and MCM+S (empty squares). Data for 85% sa-
turated systems was previously presented in (Ilie et al.,
2020b) and are depicted here for comparative purposes
with in vivo results for supersaturated systems.
Table 2
Dose-normalized pharmacokinetic parameters Cmax, AUC0–24 h (mean ± SD) and tmax (median, [min, max]) following single oral administration of LBDDS at 85%
saturated or supersaturated celecoxib (n = 4). Statistics represent pairwise comparisons.
LBDDS LCM MCM LCM+S MCM+S
aDS 85% saturated Supersaturated 85% saturated Supersaturated 85% saturated Supersaturated 85% saturated Supersaturated
Cmax (ng/mL) 429 ± 78a 506 ± 137b 237 ± 52a 308 ± 19b 325.6 ± 7.1 286.7 ± 69.7b 270 ± 63a 249 ± 43.3b
AUC 0–24 h (ng/mL*h) 3563.5 ± 984.5c 4145 ± 1062d 1978.6 ± 243.6c,f 3626.2 ± 519.8e,f 3126.6 ± 251.3 3085.2 ± 651.3 2776 ± 354 2203 ± 274d,e
tmax (h) 1.5 [1.0; 4.0]g 4.0 [4.0; 4.0]g 4.0 [2.0; 4.0] 4.0 [2.0; 8.0] 3.0 [1.0; 4.0] 4.0 [4.0; 4.0] 3.0 [2.0; 4.0] 4.0 [4.0; 4.0]
F (%) 88 ± 21h 103 ± 23i 49.1 ± 5.2h,k 90 ± 11j,k 77.6 ± 5.4 77 ± 14 68.9 ± 7.6 54.7 ± 5.9i,j
a Cmax: LCM statistically significant from MCM and MCM+S (85% saturated);.
b Cmax: sLCM statistically significant from all other tested supersaturated LBDDS;
c AUC0–24h: LCM statistically different from MCM (85% saturated);.
d AUC0–24h: sLCM statistically different from sMCM+S (supersaturated);.
e AUC0–24h: sMCM statistically different from sMCM+S;.
f AUC0–24h: sMCM statistically different from MCM;
g tmax: sLCM statistically significant longer relative to LCM.
h F: LCM statistically significant from MCM (85% saturated);.
i F: sLCM statistically significant from sMCM+S (supersaturated);.
j F: sMCM statistically significant from sMCM+S (supersaturated);.
k F: sMCM statistically different from MCM. Calculated i.v. AUC0–24 h value was 4030 ± 271 ng/mL*h.
Fig. 3. Dose-normalized area under the concentration-time plasma profiles
(mean + SD) obtained after oral administration of (s)LBDDS containing cel-
ecoxib (n = 4)). Full bars represent 85% saturated LBDDS and bars with lines
represent supersaturated LBDDS. Statistics represent pairwise comparison. Data
for 85% saturated systems was previously presented in (Ilie et al., 2020b) and
are depicted here for comparative purposes with in vivo results for super-
saturated systems.
A.-R. Ilie, et al. European Journal of Pharmaceutical Sciences 152 (2020) 105452
6
in a side-by-side setup across PermeapadⓇ is presented in Fig. 4 (A,
dispersions and B, digests). A general trend towards lower flux values
for supersaturated LBDDS was observed relative to their corresponding
non-supersaturated systems, and in the case of sLCM versus LCM the
difference was statistically significant (p<0.05). In terms of composi-
tional effects, the flux of LCM dispersion was statistically higher relative
to MCM, sLCM and sMCM dispersions (Fig. 4A). In addition, in the post-
digested state drug flux for the LCM system was also statistically higher
relative to MCM digest (Fig. 4B). Additionally, another compositional
effect was observed for the precipitation propensity between LC and MC
systems, with drug precipitate evident on dispersion of the MC systems,
whereas no drug precipitation was visible for LC systems.
As an alternative to comparing flux parameters, given that the dose
loading varied between LBDDS, the total amount and % of drug per-
meated across the membrane into the acceptor compartment after 5 h
was calculated, relative to the concentration of drug at the beginning of
the experiment (Table 3). Allowing for the different doses, calculation
of % permeated indicated that the supersaturated systems did not in-
crease permeation, with no significant differences observed between
the sMCM relative to MCM system (0.008 ± 0.004% and
0.004 ± 0.001% for dispersions and 0.005 ± 0.001% and
0.004 ± 0.001% after digestion). Similar to the observations based on
flux, the % permeated was lower for the sLCM relative to LCM
(0.010 ± 0.003% and 0.015 ± 0.006% respectively as dispersions),
albeit not significant in this case. In terms of compositional effects, %
drug permeated from LCM and sLCM were generally higher (non-sig-
nificant) than for the corresponding MC systems which is in line with
flux observations.
Subsequently, digestion effect was assessed using simulated diges-
tion conditions that mimic in vivo conditions in the rat. It was apparent
that for all four (s)LBDDS, the flux was higher when dispersions of the
lipid systems were used in the donor compartment of the side-by-side
setup in comparison to the respective pancreatin-digested lipid systems.
Statistical differences were found for both non-supersaturated LCM and
MCM with higher flux values from dispersions compared to digested
versions (Table 3). The statistically significant compositional effect of
higher flux from LCM versus MCM was also identified in the digested
state.
3.3. In vitro dynamic drug permeation across PermeapadⓇ membrane in
Permealoop™
The dynamic PermeaLoop™ model can achieve continuous flow of
donor and acceptor media in the system and thus ensure dynamic flow-
through conditions for better assessment of interplay between disper-
sion/digestion and permeation. A plot of the cumulative amount per-
meated as a function of time and the calculated % permeated after 4 h
are illustrated in Fig. 5 and Table 4, respectively. The advantage of
higher surface area for permeation resulted in higher amount and %
drug permeated relative to the static conditions. The results illustrated
that under dynamic flow conditions the supersaturation state did not
increase the % permeated for sMCM (3.2 ± 0.4%) versus MCM
(2.7 ± 0.7%), which was in line with observations from the side-by-
side model. A reduction in permeation was also observed with dynamic
conditions for sLCM relative to LCM (6.0 ± 2.0% and 11.9 ± 5.2%).
With regards to compositional effects both at non-supersaturated and
supersaturated aDS, utilisation of LC systems resulted in higher drug
permeated (as percentage of dose) relative to the MC systems. A sta-
tistically significant difference was identified for LCM compared to
MCM and sMCM. This further supported the fact that % permeated
Fig. 4. Side-by-side permeation data of celecoxib LBDDS at 85% or supersaturated drug loadings either as dispersed (A) or digested (B) versions of the drug delivery
systems in rat simulated intestinal fluid using a biomimetic PermeapadⓇ permeation membrane. Results shown as mean + SD and statistics represent multiple
pairwise comparison in the dispersions and digests groups.
Table 3
Permeation data (flux, amount permeated, % permeated) obtained during side-by-side permeation studies with dispersion and digests of 85% saturated and su-
persaturated LBDDS. Statistics represent multiple pairwise comparison to identify differences between dispersions and digests in either non-supersaturated or
supersaturated LBDDSs.
LBDDS Dispersions Digests
Flux (µg/cm2•h) Amount permeated (µg) % permeated (5 h) Flux (µg/cm2•h) Amount permeated (µg) % permeated (5 h)
sLCM 11.4 ± 0.8 0.6 ± 0.2 0.010 ± 0.003 7.4 ± 1.9 1.3 ± 0.9 0.018 ± 0.013
LCM 15.4 ± 1.5a 0.5 ± 0.2 0.015 ± 0.006 10.4 ± 0.7a,c 0.6 ± 0.0 0.015 ± 0.001
sMCM 8.3 ± 1.3 1.7 ± 0.8 0.008 ± 0.004 7.1 ± 0.4 1.0 ± 0.1 0.005 ± 0.001
MCM 10.6 ± 1.1b 0.6 ± 0.1 0.004 ± 0.001 7.0 ± 1.5a,b,c 0.7 ± 0.1 0.004 ± 0.001
a Flux: LCM dispersion statistically different from LCM digest, MCM dispersed and MCM digest.
b Flux: MCM dispersion statistically different from MCM digest.
c Flux: LCM digest statistically different from MCM digest.
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under dynamic conditions allowed for a better comparison given the
use of different doses between LBDDS.
4. Discussion
Increasing drug loadings in LBDDS by thermally-induced super-
saturation has resulted in improved bioavailability for some drugs in
preclinical pharmacokinetic studies. However, studies that have eval-
uated sLBDDS using the common lipolysis pH-stat in vitro methods,
have failed to show the potential to improve in vivo performance using
supersaturated systems relative to a non-supersaturated system
(Thomas et al., 2014; Siqueira et al., 2017). This suggests a limitation
for the standard single stage digestion model, and that there is a need to
further investigate the effects of sLBDDS using bio-predictive in vitro
models that combine both dispersion/digestion of LBDDS with an ab-
sorptive sink. In this study, the performance of LBDDS at either non-
supersaturated or supersaturated drug loadings were tested in vivo in
rats and in vitro using two novel models with the PermeapadⓇ per-
meation membrane. Compositional effects such as differences in fatty
acid chain length were also evaluated in vitro and in vivo and addition of
surfactant in composition of LC and MC LBDDS was assessed in vivo.
Typically, in vivo performance of sLBDDS has been investigated
using a well-studied complex lipid system consisting of 4 excipients
(triglycerides, blends of mono-/di-glycerides, surfactant and co-sol-
vent). Therefore, the majority of studies reported in the literature
comparing non-supersaturated and supersaturated LBDDS have used
the same drug dose, which resulted in administration of less lipid vo-
lume in the case of sLBDDS (Siqueira et al., 2017; Michaelsen et al.,
2016; Thomas et al., 2014). Nevertheless, administration of a lower
amount of lipid in the formulation may underpredict the benefits of
supersaturated systems given the direct participation of LBDDS com-
ponents in generation and maintenance of an increased solubilization
capacity for PWSD upon dispersion in GI fluids. In contrast, the present
work focused on the head-to-head in vivo comparison of four LBDDS
consisting of either single or two components LBDDS and the sub-
sequent administration of the same lipid volume. The limitation of such
approach was that the dose of drug was variable, depending on the
solubility in lipids, why the data needed to be dose-normalized. Using
this experimental approach, overall, supersaturation had a significant
positive effect on celecoxib exposure after administration of super-
saturated sLCM and sMCM systems relative to non-supersaturated sys-
tems. Therefore, this study demonstrated the merits of higher drug
loaded sLBDDS for increasing exposure of drug, which could be parti-
cularly relevant for preclinical safety and toxicology studies. Dose in-
creases of 1.9-fold or 1.3-fold for single component LC and MC systems
resulted in increases of 2.3 and 2.4-fold in drug exposure (calculations
before dose-normalization of AUC0–24 h). Addition of surfactant resulted
in minimal exposure benefits at either drug loadings. Nevertheless, the
supersaturation approach may still be useful in early preclinical safety
studies, given the simplicity of the studied systems for rapid screening
of a dose range. Overall, the study showed that using a low-technology
input (i.e. heating to 60°C) for formulation of supersaturated lipid
systems, formulation scientists are able to load higher doses of a PWSD
in compositionally simple formulations and can achieve increased ex-
posure upon oral administration.
In order to gain additional mechanistic understanding into the su-
persaturation and composition effects on the interplay between dis-
persion/digestion and permeation, the (s)LCM and (s)MCM systems
were assessed in a side-by-side permeation setup using the biomimetic
membrane PermeapadⓇ. Interestingly, our findings indicated that su-
persaturated LBDDS did not increase drug flux, but rather paradoxically
decreased steady-state flux relative to equivalent non-supersaturated
LBDDS. In the case of LCM systems, the flux of the supersaturated
system was statistically lower than the flux of non-supersaturated
system. Possible reasons why the LCM system, which contained the
lowest drug load and thus lowest total drug concentration, displayed
the highest flux were unclear, but may reflect that upon dispersion of
such a system, the drug will be dissolved either freely (i.e. molecularly
dissolved) or solubilized within the colloidal assemblies that form.
Higher flux for the LCM system may reflect that this dispersion was
favourable for maintaining free drug concentrations in the aqueous
medium, which continues to permeate across the membrane. In con-
trast, increasing the dose loading, as in the case of supersaturated LCM,
did not lead to further increases in flux. This may indicate that the
relative amount of free drug in the aqueous media of supersaturated
systems was lower than in non-supersaturated systems. Alternatively,
despite higher total drug concentrations for the sLCM systems, due to
higher partitioning of drug within the colloidal oil droplets, the su-
persaturated system did not readily maintain the free drug concentra-
tions in the aqueous medium under conditions of ongoing drug per-
meation. Therefore, further studies at different dose loading are
required to delineate if the increased dose load due to supersaturation
results in proportionate increases in both free and colloidally associated
drugs on dispersion.
This study also explored compositional effects to increase drug ex-
posure and showed that LC systems increased celecoxib bioavailability
over MC systems at both non-supersaturated and supersaturated dose
loadings. In contrast, addition of surfactant had no positive influence on
Fig. 5. Graphical representation of the amount permeated in time across the PermeapadⓇ membrane in a dynamic dispersion-permeation study using PermeaLoop™.
Table 4
Amount permeated and corresponding %permeated obtained after evaluation
of dynamic dispersion-permeation PermeaLoop™ model of dispersions of 85%
saturated and supersaturated LBDDS containing celecoxib.
LBDDS Amount permeated (µg) % permeated (4 h)
sLCM 648 ± 212 6.0 ± 2.0
LCM 780 ± 342 11.9 ± 5.2a
sMCM 1149 ± 152 3.2 ± 0.4a
MCM 754 ± 194 2.7 ± 0.7a
a LCM % permeated statistically significantly higher than MCM and sMCM.
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celecoxib exposure at the two dose loadings. Looking at the impact of
composition on permeation in this side-by-side setup flux and % per-
meated results would indicate that LCM systems yielded higher overall
permeation relative to MCM systems. This was observed in both dis-
persed and digested states and was statistically significant for non-su-
persaturated systems, i.e. LCM relative to MCM.
The relatively small area-to-volume ratio (i.e. 0.25 cm−1) of the
side-by-side setup was likely to be a factor in the relatively low overall
values for % drug permeated (between 0.004 ± 0.001% and
0.018 ± 0.013%). The low A/V ratio was also regarded as a main
limitation of the setup, which may also be a factor in the lack of sig-
nificant differences observed between the various formulations tested
i.e. limited ability to differentiate between formulations under low A/V
steady-state flux conditions. Therefore, the PermeaLoop™ setup, with a
higher A/V ratio of 1.38 cm−1, offered additional insights into the in-
fluence of drug supersaturation and compositional effects on celecoxib
permeation in a dynamic dissolution-permeation setup. Overall, the %
permeated values were higher (between 2.7 ± 0.7% and
11.9 ± 5.2%) than in the side-by-side setup. The PermeaLoop™ model
was generally in line with the steady-state model, i.e. supersaturation
increased flux for the MCM system, but overall, no significant differ-
ences were observed for the supersaturation effects in the dynamic
model. In terms of compositional effects, the dynamic flow model re-
vealed similar observations to both the in vivo data and the static model;
however, in contrast to the static model it revealed the statistically
significant higher LCM % permeation, with 11.9 ± 5.2% of the dose
appearing in the acceptor media after 4 h, compared to 2.7 ± 0.7% for
the MCM system (p = 0.017) and 3.2 ± 0.4% for sMCM (p = 0.022)
(Table 4).
Digestion is believed to play an important role in absorption pro-
cesses of PWSD from LBDDS, which has guided research towards es-
tablishing increasingly complex lipolysis models (Iwanaga et al., 2006;
Yeap et al., 2013; Berthelsen et al., 2019). In the present study, the
difference in celecoxib permeability between dispersions and digests of
LCM and MCM was also assessed in a steady-state diffusion setup using
conditions that simulated the rat intestine. Results indicated that a
higher flux was obtained in the dispersed state of either non-super-
saturated or supersaturated LBDDS, compared to corresponding di-
gested states. The results indicated statistically significant differences
between LCM dispersions (15.4 ± 1.6) and digests (10.4 ± 0.7) and
between MCM dispersions (10.6 ± 1.1) and digests (6.9 ± 1.5). This
could be a result of increased solubilization capacity of the post-di-
gestive state, where digested lipids served to increase solubilisation
capacity of bile salt-lipid micelles, which could overall reduce the
available fraction of free drug that can further permeate across the
membrane. In support of this, higher apparent solubilities of celecoxib
were observed in simulated digested LCM and MCM biorelevant media
relative to dispersed lipids (Ilie et al., 2020b). Similarly, a recent ob-
servation by Jacobsen et al. indicated a higher solubilisation capacity
for celecoxib by monoacyl-phospholipids as compared to diacyl-phos-
pholipids, the former representing the lipolytic degradation product of
the latter, which was in line with the outlined hypothesis of increased
solubilisation in media with lipolytic end-products (Jacobsen et al.,
2019). Collectively therefore, this may suggest that the post-digestive
conditions may lead to lower steady-state flux, at least in models where
the lipids/surfactant molecules do not readily permeate across the
membrane. These observations may lend further support to the concept
of developing digestion-independent or ‘stealth’ LBDDS to increase drug
absorption (Feeney et al., 2014).
While the overall flux was lower under simulated digestive condi-
tions, the higher flux from the LCM system was still maintained relative
to the MCM system under post-digestive state. Biorelevant solubility
determinations showed higher solubilisation capacity of celecoxib in
simulated post-digestive MCM systems, compared to LCM equivalents
(Ilie et al., 2020b). Therefore, it appeared that the higher solubilization
capacity in the colloidal environment did not directly translate to in-
creased permeation across the biomimetic membrane. The higher flux
observed for LC systems may in part explain the improved in vivo
bioavailability observed for LCM systems. Alternatively, the relatively
poor performance of MCM systems may have reflected a higher pre-
cipitation risk from MC systems as observed in a study by Sek et al.
whereby MC blends of mono-/di-glycerides were rapidly digested,
forming an aqueous dispersed phase or a precipitated fraction
(Sek et al., 2002). In contrast, LC blends of glycerides were more slowly
digested, the undigested oily phase still being present throughout the
30-minutes digestion (Sek et al., 2002). A similar higher propensity for
precipitation in MCM versus LCM systems was visually observed in the
donor compartment in the present study.
Relating in vitro results to in vivo data has been a strong focus of
research groups over the past decades. In the present study, a first at-
tempt to relate in vitro permeation data from two different models to in
vivo results obtained after administration of non-supersaturated and
supersaturated LBDDS was made and is summarized in Table 5. Using
the steady-state model, flux did not anticipate the better in vivo per-
formance of supersaturated LBDDS compared to non-supersaturated
systems and the dose-normalised data (i.e. % permeated) suggested a
trend towards higher permeation for supersaturated systems, though no
overall significant differences were observed (p>0.05). In contrast, the
compositional effects seen in vivo were predicted based on the higher
flux of LC systems over MC systems. Similarly, the higher permeability
effect of LCM versus MCM (3.8-fold for both dispersions and digests)
and sLCM versus sMCM (1.3-fold for dispersions and 3.6-fold for di-
gests) was evident when comparing % permeated at steady-state. Di-
gestion was shown to have a negative impact on flux of tested (s)LBDDS
and overall had a limited benefit in vitro testing also considering the
increased resource and time investment needed to run this experi-
mental design. Therefore, while it is desirable to create in vivo-adapted
biopharmaceutical in vitro models, it may also be useful during early
Table 5
Summary of findings after in vivo and in vitro evaluation of non-supersaturated (85%) and supersaturated lipid-based drug delivery systems containing celecoxib.
In vivo PermeapadⓇ PermeaLoop™
AUC Flux % perm % perm
Supersaturation sMCM versus MCM Y (p<0.05) N Y (p>0.05) Y(p>0.05)
sLCM versus LCM Y (p>0.05) N* N N
Composition LCM versus MCM Y (p<0.05) Y (p<0.05) Y (p>0.05) Y (p<0.05)
sLCM versus sMCM Y (p>0.05) Y (p>0.05) Y (p>0.05) Y (p>0.05)
MCM+S/LCM+ S versus MCM/LCM N N/A N/A N/A
Digestion sMCM versus MCM N/A Y (p>0.05) Y (p>0.05) N/A
sLCM versus LCM N Y (p>0.05)
LCM versus MCM Y (p<0.05) Y (p>0.05)
sLCM versus sMCM Y (p>0.05) Y (p>0.05)
Y = yes effect observed ( ± statistically significant difference); N = no effect observed;.
N* = statistically significant opposite effect; N/A = not applicable.
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stage drug development to assess the in vitro performance of bio-en-
abling lipid formulations with more simplistic (i.e. without digestive
conditions) models which have predictive potential for in vivo perfor-
mance. A first attempt was outlined in this study in terms of using the
rat biorelevant rat media, readily available dispersions of (s)LBDDS and
dynamic flow conditions maintained by the PermeaLoop™ model. With
this new model, a different permeation profile was observed compared
to a steady-state setup (Figure S1 and Fig. 5). The statistically sig-
nificant difference observed between LCM and MCM % permeated was
correctly identified with the dynamic model. During a dispersion-per-
meation study, steady-state conditions were observed if the permeation
was rate limiting. In the case of PermeaLoop™ the cumulated amount
permeated curve deviated from a straight line and tended asymptoti-
cally towards a constant value. This suggested that the amount per-
meated was highly dependant on the release of free drug from the
formulation, which was especially relevant for bio-enabling formula-
tions such as LBDDS. Further developments to the model are en-
couraged in terms of optimization of flow rates, dilution volumes, pH
adjustments, dispersion and acceptor media, in order to improve ro-
bustness and bio-relevance of the model.
5. Conclusions
The present study demonstrated that at equivalent lipid doses, in-
creasing the drug saturation above equilibrium solubility resulted in an
increased in vivo bioavailability of celecoxib from single component
LBDDS relative to the corresponding non-supersaturated LBDDS. Using
the in vitro PermeapadⓇ model, while supersaturation in LBDDS did not
reveal higher flux across the biomimetic membrane, the beneficial
impact of LCM system versus MCM system was observed, similar to
observations in vivo. This study demonstrated the utility to explore di-
gestion-permeation, with studies demonstrating that steady-state flux
was lower under post-digestive conditions, but compositional difference
was still evident. Possible reasons for this may reflect the dynamic in-
terplay between molecularly dissolved drug and colloidally associated
drug, and the associated impact on steady-state permeation through the
membrane. Proof-of-concept studies in the PermeaLoop™ dynamic flow
model confirmed a statistically significantly higher % permeated for LC
versus comparable MC systems, which would suggest that % permeated
was a more useful parameter to compare formulations than the steady-
state flux. Overall, these in vivo and in vitro studies provided a frame-
work for demonstrating the utility of dispersion/digestion-permeation
models to explore the dynamic and complex solubility-permeation in-
terplay in (s)LBDDS. Further studies on supersaturation and/or com-
positional approaches to maximise permeation under both steady-state
and dynamic flow are merited.
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